Dartmouth–Hitchcock Medical Center, the flagship campus of the Dartmouth Health system, is the U.S. state of New Hampshire's only academic medical center. DHMC is a 422-inpatient bed hospital and serves as a major tertiary-care referral site for patients throughout northern New England.

There are 422 beds in Dartmouth Health.

During the past decade, Dartmouth Health conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 1 clinical trials were completed, i.e. on average, 7.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dartmouth Health" #1 sponsor was "Dartmouth-Hitchcock Medical Center" with 6 trials, followed by "Merck Sharp & Dohme LLC" with 4 trials sponsored, "Barbara Jobst" with 1 trials sponsored, "Duke University" with 1 trials sponsored and "Inspirna, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dartmouth Health" #1 collaborator was "Centers for Disease Control and Prevention" with 1 trials as a collaborator, "Dartmouth-Hitchcock Medical Center" with 1 trials as a collaborator, "Disarm Therapeutics" with 1 trials as a collaborator, "Duke Health" with 1 trials as a collaborator and "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Dartmouth Health" are "Carcinoma, Non-Small-Cell Lung" (4 trials), "Epilepsy" (2 trials), "Abdominal Aortic Aneurysms" (1 trials), "Advanced Cancer" (1 trials) and "CIPN - Chemotherapy-Induced Peripheral Neuropathy" (1 trials). Many other conditions were trialed in "Dartmouth Health" in a lesser frequency.

Most popular intervention types in "Dartmouth Health" are "Drug" (4 trials), "Biological" (3 trials), "Diagnostic Test" (3 trials), "Behavioral" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (4 trials), "MK-0482" (3 trials), "MK-4830" (3 trials), "Boserolimab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Dartmouth Health" are 15 trials for "All" genders.

Currently, there are 10 active trials in "Dartmouth Health". 1 are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 5 completed trials in Dartmouth Health, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dartmouth Health, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 8 trials that are defined as “Not Applicable".